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To the Editor:
Polycythemia vera (PV) is a chronic myeloproliferative
neoplasm (cMPN) characterized by stem cell-derived clonal
myeloproliferation resulting in panmyelosis with persis-
tently raised hematocrit, increased risk of thrombotic com-
plications, and predisposition to evolve to myelofibrosis or
leukemia [1]. Therapy is currently based on phlebotomy to
normalize hematocrit, and aspirin. Hydroxyurea is used as
first line when cytoreduction is necessary [1], although
toxicity can result in inadequate disease management [2].
Recently, ropeginterferon α-2b was approved by European
Medicinal Agency as first line for patients without symp-
tomatic splenomegaly [3]. Ruxolitinib is second-line for
patients who are refractory and/or intolerant to hydroxyurea
[4]; other treatments include busulfan, pipobroman [5], and
nonpegylated and pegylated interferons (off-label) [1, 6, 7],
but use is limited by side effects and safety concerns.
Additional, targeted therapies are therefore needed.
Up to 98% of patients with PV bear the JAK2V617F gene
mutation, which activates erythropoietin receptor signaling
pathways. Givinostat is a histone-deacetylase (HDAC)
inhibitor that selectively targets JAK2V617F cell growth,
reducing hematopoietic cell proliferation [8]. The efficacy
and safety of givinostat alone or with hydroxyurea has
previously been evaluated in two studies in JAK2V617F
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positive PV [9, 10]. Although these studies confirmed the
positive risk-benefit of givinostat, they did not provide
comprehensive efficacy evidence for givinostat mono-
therapy, and did not identify the most appropriate dose. The
current study was therefore conducted to support givinostat
monotherapy development in PV, aiming to determine the
maximum tolerated dose (MTD), and to assess safety and
efficacy of this dose.
This multinational, open-label, nonrandomized study
was conducted in two parts. Part A (Phase Ib) was dose
escalation, with the first 4-week cycle determining the
MTD. Part B (Phase II), the proof of concept phase, then
evaluated efficacy and safety at this MTD. Full details of the
methods are in the supplement. Both parts had 24-week
treatment periods, with patients receiving six four-week
cycles of givinostat. In Part A, since givinostat 50 mg twice
daily (BID) was previously well tolerated, the first cohort of
three patients received 100 mg BID, with the dose to be
escalated by 50 mg BID in each subsequent cohort
according to a 3+ 3 design, adopting a modified Fibonacci
escalation scheme, although only after the third patient had
been followed for a minimum of one cycle, and tolerability
data had been evaluated by the Safety Review Team
(Supplementary Table 1). For Part B, patients initially
received givinostat at the MTD, with modification permitted
to achieve an optimized dose, balancing tolerability, and
response.
Eligible patients were aged ≥18 years, with a confirmed
PV diagnosis, JAK2V617F positivity assessed by centralized
quantitative real-time polymerase chain reaction, and active/
not controlled disease, defined as: (1) hematocrit ≥45% or
<45% with phlebotomy, and (2) platelet count >400 × 109/l,
and (3) white blood cell count >10 × 109/l. Main exclusion
criteria were: absolute neutrophil count <1.2 × 109/l; prior
JAK2 or HDAC inhibitor treatment; systemic treatment for
cMPNs other than aspirin; hydroxyurea, interferon alpha, or
anagrelide within 28, 14, or 7 days before enrollment,
respectively. All patients provided informed consent. Study
registration: ClinicalTrials.gov (NCT01901432).
The primary objectives of Part A were to determine
givinostat’s MTD, and to characterize safety and tolerability
in terms of treatment-related adverse events (AEs). Sec-
ondary endpoints were to evaluate overall response after
three and six cycles (using the clinico-hematological Eur-
opean LeukemiaNet (ELN) response criteria [11]), and to
characterize pharmacokinetics. For Part B, primary objec-
tives were to evaluate overall response, safety and toler-
ability after three cycles. Secondary endpoints were to
evaluate overall response, safety and tolerability after six
cycles, and to characterize pharmacokinetics. Exploratory
endpoints are in the supplement.
Twelve patients were studied in Part A, with 35 in Part B
(Supplementary Fig. 1, Supplementary Tables 2 and 3). In
Part A, during the first cycle one patient receiving givinostat
100 mg BID experienced dose-limiting toxicity: Grade 3
dyspepsia, drug related, resolving with sequelae after
treatment. Three additional patients therefore received
100 mg BID, none of whom had dose-limiting toxicity
during Cycle 1. Although escalation to higher doses was
permitted, the Safety Review Team agreed the MTD was
100 mg BID, given: (a) thrombocytopenia is a known side
effect of HDAC inhibitors; (b) a platelet count decrease was
observed in subsequent cycles; (c) as givinostat is a chronic
treatment, it was preferable to not expose patients to higher
doses that could be poorly tolerated during chronic treat-
ment. To more accurately define givinostat’s MTD, three
additional patients received an intermediate dose (150 mg
daily). Finally, three patients received 50 mg BID, to
investigate safety, pharmacokinetics, and pharmacody-
namics of this dose. A total of 66.7% of patients experi-
enced at least one drug-related AE, mainly Grade 1 or 2
(Supplementary Table 4), most commonly thrombocytope-
nia (33.3% of patients). Two patients (16.7%) experienced a
serious AE (thrombophlebitis and myocardial infarction),
neither drug-related; no patient died. Two patients withdrew
due to drug-related AEs (dyspepsia [Grade 3] and throm-
bocytopenia [Grade 4]), both with 100 mg BID.
The overall response rate in Part A was above 70%
(Fig. 1). One patient achieved complete response after three
cycles, and one after six cycles. Median givinostat Tmax was
1.5–4 h (Supplementary Table 5), with steady-state reached
by day 28 of Cycle 1 (the first repeat-dose pharmacokinetic
evaluation). After three cycles, givinostat normalized
hematological parameters in 45.5–54.5% of patients (Sup-
plementary Table 6), normalized spleen volume in 54.5%,
resolved disease-related symptoms in 63.6% (Supplemen-
tary Table 7), and reduced pruritus and JAK2-mutated allele
burden (Supplementary Table 8).
Fig. 1 Parts A and B: therapeutic response evaluation (intention-
to-treat population). Data are from 11 patients in Part A and 31
patients in Part B.
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At the end of Cycles 3 and 6 of Part B, 80.6% of
patients were responders (Fig. 1), with three achieving
complete response after three cycles and one after six.
Overall, 94.3% of patients had at least one drug-related
AE, the majority Grade 1 or 2 and none Grade 4 or 5, with
most occurring during the first three cycles of treatment
(152 out of 190 events). The most common were diarrhea
(51.4% of patients), thrombocytopenia (45.7%), and
increased blood creatinine (37.1%) (Table 1). Two
patients experienced a serious AE, both during the first
three cycles, one study drug-related (Grade 3 diarrhea
resolving in 7 days without therapy, with study drug
temporarily discontinued). Three patients withdrew, one
due to study drug-related AEs (Grade 3 neutropenia and
Grade 2 thrombocytopenia, both resolving). The other two
were withdrawn by their investigators (Supplementary
Fig. 1). No patient died, and there were no clinically
relevant vital signs or ECG values.
Overall, Part B pharmacokinetics was similar to Part A
at comparable doses (Supplementary Tables 9 and 10).
Improvements were seen in all individual response criteria
(Supplementary Fig. 2; Supplementary Table 11), with
white blood cell and platelet counts normalized in 90.3%
and 74.2% of patients after three cycles, respectively, and
hematocrit in 77.4% and 48.4% after three and six cycles,
respectively. Improvements were observed in disease-
related symptoms assessed by Myeloproliferative Neo-
plasm Symptom Assessment Form quality of life (QoL)
questionnaire, especially during Cycle 6 (Supplementary
Table 12), with a reduction in the proportion with severe
pruritus (Score 7–10; Supplementary Fig. 3). Approxi-
mately 50% had no headache (Supplementary Table 12),
and no patients had severe headache (Supplementary
Fig. 4). The proportion of patients without microvascular
symptoms improved from baseline (38.7%) to Cycle 6
(51.6%; Supplementary Table 12), with a low proportion
having severe symptoms (6.5–12.9%; Supplementary
Fig. 5). A total of 19.4% had a spleen volumetric index
reduction of at least 35% during treatment, with total spleen
normalization in two and three patients after three and six
cycles, respectively, and a moderate reduction in JAK2V617F
allele burden (Supplementary Table 12). Finally, differential
gene expression was observed (Supplementary Fig. 6), with
upregulation for GLRX, STAT4 and HDAC3, and down-
regulation for MYC.
The study aims were achieved, with the MTD, 100 mg
BID, determined in Part A, and this dose effective in Part
B. In addition to the high overall response rate, givinostat
had a positive impact on individual clinico-hematological
ELN criteria, both hematological parameters and disease-
related symptoms. The three hematological parameters, all
abnormal at study entry, were normalized in the majority of
patients, and givinostat improved key disease-related
symptoms, notably pruritus with complete resolution in
many patients, with an associated positive impact on QoL.
A reduction in JAK2-mutated allele burden was observed in
both parts of the study, and Part B provided clear evidence
of differential gene expression with givinostat, consistent
with disease pathway regulation. Overall, givinostat was
well tolerated with no new safety concerns. Unlike previous
studies, the recruited population had active or not controlled
disease, and were both high- and low-risk, making com-
parisons difficult. However, the observed response was
greater than for other PV therapies [12–15]. For example, in
a study comparing interferon to hydroxyurea, 45% of
patients had a hematologic response to either therapy [12],
whereas in a second study, 40% of patients had a response
of any type to ruxolitinib [13], and in a third the overall
response to the HDAC inhibitor vorinostat was 35%, with
significant side effects resulting in a high rate of study
withdrawal [15].
Table 1 Part B: patients with study drug-related treatment-emergent
AEs, overall and by system organ class and preferred term (including
only preferred terms reported by one or more patient with Grade 3
events) (safety population).
System organ class preferred term Grade 3 Any
grade
N % N %
Patients with any drug-related AE 10 28.6 33 94.3
Blood and lymphatic system disorders 3 8.6 18 51.4
Anemia 2 5.7 6 17.1
Neutropenia 1 2.9 2 5.7
Thrombocytopenia 1 2.9 16 45.7
Cardiac disorders 0a 0 1 2.9
Gastrointestinal disorders 4 11.4 26 74.3
Diarrhea 4 11.4 18 51.4
General disorders and administration site
conditions
2 5.7 9 25.7
Asthenia 2 5.7 8 22.9
Investigations 0a 0 19 54.3
Metabolism and nutrition disorders 1 2.9 8 22.9
Hypocalcemia 1 2.9 4 11.4
Nervous system disorders 0a 0 5 14.3
Renal and urinary disorders 0a 0 2 5.7
Respiratory, thoracic and mediastinal disorders 0a 0 1 2.9
Skin and subcutaneous tissue disorders 1 2.9 6 17.1
Rash 1 2.9 1 2.9
Data are from 35 patients. Grades are based on the National Cancer
Institute Common Terminology Criteria for Adverse Events Version
4.03, where Grade 1 are mild events, Grade 2 are moderate, Grade 3
are severe, Grade 4 are life-threatening, and Grade 5 events result in
death. There were no Grade 4 or 5 events in Part B of the study.
AE adverse event.
aThere were no Grade 3 events for these system organ classes.
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In conclusion, these data support givinostat monotherapy
development in the defined PV target population.
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